22 May 2013
Keywords: paul, royalty, buy, estorra, rights, aventis, 115m
Article | 16 August 2004
The New York, USA-based Paul Royalty Fund will, subject to thecompletion of the Sanofi-Synthelabo acquisition of Aventis, acquire
from the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
16 August 2004
21 May 2013
© 2013 thepharmaletter.com